1. Home
  2. MYI vs DNTH Comparison

MYI vs DNTH Comparison

Compare MYI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYI
  • DNTH
  • Stock Information
  • Founded
  • MYI 1992
  • DNTH 2015
  • Country
  • MYI United States
  • DNTH United States
  • Employees
  • MYI N/A
  • DNTH N/A
  • Industry
  • MYI Investment Bankers/Brokers/Service
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • MYI Finance
  • DNTH Health Care
  • Exchange
  • MYI Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • MYI 723.2M
  • DNTH 657.0M
  • IPO Year
  • MYI N/A
  • DNTH N/A
  • Fundamental
  • Price
  • MYI $10.45
  • DNTH $17.39
  • Analyst Decision
  • MYI
  • DNTH Strong Buy
  • Analyst Count
  • MYI 0
  • DNTH 8
  • Target Price
  • MYI N/A
  • DNTH $53.00
  • AVG Volume (30 Days)
  • MYI 256.7K
  • DNTH 255.5K
  • Earning Date
  • MYI 01-01-0001
  • DNTH 05-12-2025
  • Dividend Yield
  • MYI 4.81%
  • DNTH N/A
  • EPS Growth
  • MYI N/A
  • DNTH N/A
  • EPS
  • MYI N/A
  • DNTH N/A
  • Revenue
  • MYI N/A
  • DNTH $6,524,000.00
  • Revenue This Year
  • MYI N/A
  • DNTH N/A
  • Revenue Next Year
  • MYI N/A
  • DNTH N/A
  • P/E Ratio
  • MYI N/A
  • DNTH N/A
  • Revenue Growth
  • MYI N/A
  • DNTH 102.36
  • 52 Week Low
  • MYI $9.32
  • DNTH $13.37
  • 52 Week High
  • MYI $11.70
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • MYI 44.98
  • DNTH 35.86
  • Support Level
  • MYI $10.37
  • DNTH $17.40
  • Resistance Level
  • MYI $10.51
  • DNTH $18.45
  • Average True Range (ATR)
  • MYI 0.11
  • DNTH 1.21
  • MACD
  • MYI -0.01
  • DNTH -0.22
  • Stochastic Oscillator
  • MYI 38.69
  • DNTH 10.60

About MYI Blackrock MuniYield Quality Fund III Inc

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: